Methodology & Disclosures: The 2026 GLP-1 Consumer Experience Survey

The survey will recruit participants through Prolific, an online research panel platform widely used in academic and market research. Prolific provides pre-screened participant pools with verified demographic profiles.

• Participants will be screened for self-reported current or recent GLP-1 medication use
• Target sample size: n=500+ completed responses
• U.S. adults aged 18 and older
• Quota sampling will be used to ensure demographic diversity across age, gender, and income brackets

Respondents will complete a multi-select medication identification question designed to confirm GLP-1 use while filtering out inattentive or dishonest respondents.

• Multi-select format listing specific GLP-1 medications (semaglutide, tirzepatide, liraglutide, etc.)
• Control options (fictitious medication names) included to detect random selection
• Respondents selecting only control options will be screened out
• Additional verification question about route of administration (injection vs. oral)

Multiple quality control measures will be implemented to ensure data integrity:

• Speeders: Responses completed in less than one-third of the median completion time will be flagged and removed
• Attention checks: Embedded instructed-response items (e.g., "Please select ‘Strongly Agree’ for this question") will appear at multiple points
• Straight-lining detection: Respondents selecting the same answer for all items in a matrix will be flagged
• Open-ended validation: Free-text responses will be reviewed for gibberish or copy-pasted content
• Exclusion criteria: Respondents who fail the screening protocol or two or more attention checks will be excluded from analysis

The questionnaire is being developed by the WPG Research Team with the following design principles:

• Balanced response scales with no leading or loaded language
• Question order randomization where appropriate to reduce order effects
• Mix of closed-ended (Likert scale, multiple choice) and open-ended questions
• Reviewed for bias, clarity, and reading level
• Pilot testing with a small sample before full deployment

The full questionnaire will be published on this page after the survey is fielded.

All research has limitations. We believe in transparent disclosure of ours:

• Opt-in sample: This is not a probability-based sample. Participants self-select into the Prolific platform and then into this study, which may introduce selection bias.
• Self-reported data: All medication use, dosages, side effects, and outcomes are self-reported and cannot be independently verified.
• Not nationally representative: While we will use quota sampling, the results should not be interpreted as nationally representative estimates.
• Cannot establish causation: This is a cross-sectional survey. Observed associations between variables do not imply causal relationships.
• Online-only: The survey is administered online, which excludes populations without internet access.

To ensure transparency and reduce the risk of data dredging, the following analyses are pre-specified before data collection begins:

• Cross-tabulations by age group (18-34, 35-54, 55+)
• Cross-tabulations by gender
• Cross-tabulations by household income bracket
• Cross-tabulations by medication type (semaglutide vs. tirzepatide vs. other)
• Cross-tabulations by duration of use (<6 months, 6-12 months, 12+ months)

Any additional analyses conducted beyond these pre-specified comparisons will be clearly labeled as exploratory in our reporting.

This research is entirely self-funded by WeightLossProviderGuide.com. No pharmaceutical company, telehealth provider, or other commercial sponsor has provided funding for this survey or its analysis.